- Home
- ZEPP vs VYGR Comparison
ZEPP vs VYGR Comparison
Compare ZEPP & VYGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ZEPP
- VYGR
- Stock Information
- Founded
- ZEPP 2013
- VYGR 2013
- Country
- ZEPP Netherlands
- VYGR United States
- Employees
- ZEPP N/A
- VYGR N/A
- Industry
- ZEPP Computer Manufacturing
- VYGR Biotechnology: Pharmaceutical Preparations
- Sector
- ZEPP Technology
- VYGR Health Care
- Exchange
- ZEPP Nasdaq
- VYGR Nasdaq
- Market Cap
- ZEPP 148.3M
- VYGR 172.6M
- IPO Year
- ZEPP N/A
- VYGR 2015
- Fundamental
- Price
- ZEPP $33.76
- VYGR $3.76
- Analyst Decision
- ZEPP
- VYGR Strong Buy
- Analyst Count
- ZEPP 0
- VYGR 7
- Target Price
- ZEPP N/A
- VYGR $14.50
- AVG Volume (30 Days)
- ZEPP 540.1K
- VYGR 846.5K
- Earning Date
- ZEPP 08-03-2025
- VYGR 08-06-2025
- Dividend Yield
- ZEPP N/A
- VYGR N/A
- EPS Growth
- ZEPP N/A
- VYGR N/A
- EPS
- ZEPP N/A
- VYGR N/A
- Revenue
- ZEPP $199,947,000.00
- VYGR $42,580,000.00
- Revenue This Year
- ZEPP $758.69
- VYGR N/A
- Revenue Next Year
- ZEPP N/A
- VYGR $78.89
- P/E Ratio
- ZEPP N/A
- VYGR N/A
- Revenue Growth
- ZEPP N/A
- VYGR N/A
- 52 Week Low
- ZEPP $2.13
- VYGR $2.65
- 52 Week High
- ZEPP $38.59
- VYGR $8.28
- Technical
- Relative Strength Index (RSI)
- ZEPP 84.42
- VYGR 64.63
- Support Level
- ZEPP $23.10
- VYGR $2.99
- Resistance Level
- ZEPP $38.59
- VYGR $3.57
- Average True Range (ATR)
- ZEPP 3.30
- VYGR 0.31
- MACD
- ZEPP 1.52
- VYGR 0.06
- Stochastic Oscillator
- ZEPP 84.23
- VYGR 98.02
About ZEPP Zepp Health Corporation
Zepp Health Corp is engaged in the business of manufacturing smart health wearable products. The company operates in one segment which is Amazfit-branded products. The product portfolio includes smartwatches and fitness bands.
About VYGR Voyager Therapeutics Inc.
Voyager Therapeutics Inc is a gene therapy company focused on developing life-changing treatments for patients suffering from severe neurological diseases. It focuses on neurological diseases where an adeno-associated virus, or AAV, gene therapy approach that either increases or decreases the production of a specific protein can slow or reduce the symptoms experienced by patients, and therefore have a clinically meaningful impact. The company's gene therapy platform TRACER enables to engineer, optimize, manufacture and deliver AAV-based gene therapies that have the potential to provide durable efficacy following a single administration. Its pipeline of programs include, Anti-tau Antibody (VY-TAU01), SOD1 Silencing Gene Therapy (siRNA), FXN Gene Therapy among others.